Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2
Blazej Dolniak1, Efstratios Katsoulidis, Nathalie Carayol
1Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Department of Medicine, Northwestern University Medical School, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60611, USA.
Abstract:
Arsenic trioxide (As(2)O(3)) is a potent inducer of apoptosis of malignant cells in vitro and in vivo, but the precise mechanisms by which it mediates such effects are not well defined. We provide evidence that As(2)O(3) induces phosphorylation/activation of the MAPK signal-integrating kinases (Mnks) 1 and 2 in leukemia cell lines. Such activation is defective in cells with targeted disruption of the p38alpha MAPK gene, indicating that it requires upstream engagement of the p38 MAPK pathway. Studies using Mnk1(-/-) or Mnk2(-/-), or double Mnk1(-/-)Mnk2(-/-) knock-out cells, establish that activation of Mnk1 and Mnk2 by arsenic trioxide regulates downstream phosphorylation of the eukaryotic initiation factor 4E at Ser-209. Importantly, arsenic-induced apoptosis is enhanced in cells with targeted disruption of the Mnk1 and/or Mnk2 genes, suggesting that these kinases are activated in a negative-feedback regulatory manner, to control generation of arsenic trioxide responses. Consistent with this, pharmacological inhibition of Mnk activity enhances the suppressive effects of arsenic trioxide on primary leukemic progenitors from patients with acute leukemias. Taken together, these findings indicate an important role for Mnk kinases, acting as negative regulators for signals that control generation of arsenic trioxide-dependent apoptosis and antileukemic responses.
Insights
Arsenic trioxide activates MAPK signal-integrating kinases (Mnks) 1 and 2, which negatively regulate its cancer-killing effects. Inhibiting Mnk kinases enhances arsenic trioxide
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- Arsenic trioxide (As(2)O(3)) induces apoptosis in malignant cells, but its precise mechanisms remain unclear.
- Understanding As(2)O(3) signaling pathways is crucial for developing targeted leukemia therapies.
Purpose of the Study:
- To elucidate the role of MAPK signal-integrating kinases (Mnks) 1 and 2 in arsenic trioxide-induced apoptosis.
- To investigate the upstream regulation of Mnk activation by the p38 MAPK pathway.
Main Methods:
- Utilized leukemia cell lines with targeted gene disruptions for p38alpha MAPK, Mnk1, and Mnk2.
- Assessed Mnk activation and downstream substrate phosphorylation (eIF4E at Ser-209) following As(2)O(3) treatment.
- Examined the impact of Mnk disruption and pharmacological inhibition on As(2)O(3)-induced apoptosis in primary leukemic progenitors.
Main Results:
- As(2)O(3) activates Mnk1 and Mnk2 in a p38 MAPK-dependent manner.
- Activated Mnks phosphorylate eukaryotic initiation factor 4E (eIF4E) at Ser-209.
- Disruption of Mnk genes enhances As(2)O(3)-induced apoptosis, indicating a negative feedback role for Mnks.
Conclusions:
- Mnk kinases act as negative regulators of As(2)O(3)-induced apoptosis and antileukemic responses.
- Pharmacological inhibition of Mnk activity potentiates As(2)O(3)'s therapeutic effects on acute leukemia cells.
- Targeting the Mnk pathway offers a potential strategy to improve As(2)O(3) efficacy in cancer treatment.
Related Concept Videos
MAPK Signaling Cascades
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Mitogens and the Cell Cycle

